CXCR2 antagonism has been shown to decrease c-Myc expression in bone marrow of patients with chronic myeloid leukemia, through a CXCR2-mTOR-c-Myc cascade (Kim et al., 2021). Here, MTOR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.